REFERENCES

1. Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA 2020;324:1980-91.

2. Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Primers 2017;3:17022.

3. Grayson M. Bladder cancer. Nature 2017;551:S33.

4. Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet 2016;388:2796-810.

5. Bhanvadia SK. Bladder cancer survivorship. Curr Urol Rep 2018;19:111.

6. Lenis AT, Lec PM, Chamie K. Bladder cancer. JAMA 2020;324:2006.

7. Massari F, Ciccarese C, Santoni M, et al. Metabolic phenotype of bladder cancer. Cancer Treat Rev 2016;45:46-57.

8. McConkey DJ, Choi W. Molecular subtypes of bladder cancer. Curr Oncol Rep 2018;20:77.

9. Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. Histopathology 2019;74:112-34.

10. Yang X, Zhou Y, Huang L, Lin S, Ye H, Shan Y. Fibroblast common serum response signature-related classification affects the tumour microenvironment and predicts prognosis in bladder cancer. Oxid Med Cell Longev 2022;2022:5645944.

11. Morales-Barrera R, Suárez C, González M, et al. The future of bladder cancer therapy: optimizing the inhibition of the fibroblast growth factor receptor. Cancer Treat Rev 2020;86:102000.

12. Chen H, Yang W, Xue X, Li Y, Jin Z, Ji Z. Integrated analysis revealed an inflammatory cancer-associated fibroblast-based subtypes with promising implications in predicting the prognosis and immunotherapeutic response of bladder cancer patients. Int J Mol Sci 2022;23:15970.

13. Mayr R, Eckstein M, Wirtz RM, et al. Prognostic and predictive value of fibroblast growth factor receptor alterations in high-grade non-muscle-invasive bladder cancer treated with and without bacillus calmette-guérin immunotherapy. Eur Urol 2022;81:606-14.

14. Necchi A, Raggi D, Giannatempo P, et al. Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study. Eur Urol Oncol 2021;4:1001-5.

15. Qin Y, Zu X, Li Y, et al. A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer. iScience 2023;26:107722.

16. Pandith AA, Shah ZA, Siddiqi MA. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol 2013;31:398-406.

17. Zhang M, Zhu J, Zhang P, et al. Development and validation of cancer-associated fibroblasts-related gene landscape in prognosis and immune microenvironment of bladder cancer. Front Oncol 2023;13:1174252.

18. Marqués M, Real FX. PIcKing on fibroblast growth factor receptors as bladder cancer therapeutic targets. Eur Urol 2017;71:863-5.

19. Zheng K, Li M. Predicting survival signature of bladder cancer related to cancer-associated fibroblast (CAF) Constructed by intersecting genes in TCGA and GEO. Mol Biotechnol 2023.

20. Caramelo B, Zagorac S, Corral S, Marqués M, Real FX. Cancer-associated fibroblasts in bladder cancer: origin, biology, and therapeutic opportunities. Eur Urol Oncol 2023;6:366-75.

21. Morales-Barrera R, Suárez C, de Castro AM, et al. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: new direction and New Hope. Cancer Treat Rev 2016;50:208-16.

22. Liu B, Zhan Y, Chen X, Hu X, Wu B, Pan S. Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression. J Cell Physiol 2021;236:1321-31.

23. Marzioni D, Lorenzi T, Mazzucchelli R, et al. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol 2009;22:627-38.

24. Yang X, Shi L, Yi C, Yang Y, Chang L, Song D. MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. Am J Cancer Res 2017;7:1738-53.

25. Barrett RL, Puré E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. Elife 2020;9:e57243.

26. Sun Y, Berleth N, Wu W, et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. Cell Death Dis 2021;12:1028.

27. Zhang D, Reyes RM, Osta E, et al. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med 2021;10:2137-52.

28. Li X, Liu H, Lv C, et al. Gypenoside-induced apoptosis via the PI3K/AKT/mTOR signaling pathway in bladder cancer. Biomed Res Int 2022;2022:9304552.

29. Md AQ, Kulkarni S, Joshua CJ, Vaichole T, Mohan S, Iwendi C. Enhanced preprocessing approach using ensemble machine learning algorithms for detecting liver disease. Biomedicines 2023;11:581.

30. Iwendi C. Innovative augmented and virtual reality applications for disease diagnosis based on integrated genetic algorithms. Int J Cognit Comput Eng 2023;4:266-76.

31. Thandapani S, Mahaboob MI, Iwendi C, et al. IoMT with deep CNN: AI-based intelligent support system for pandemic diseases. Electronics 2023;12:424.